Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy
- 29 September 2008
- journal article
- review article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 6 (10) , 829-837
Abstract
Adjuvant interferon-alpha (IFN-alpha) therapy in patients with melanoma has been established as standard therapy since more than 10 years.During IFN-alpha therapy, flu-like symptoms, gastrointestinal disorders, arthralgias and neuropsychiatric symptoms are the most common side effects. The management and prophylaxis of these side effects have been improved by a more detailed understanding of pathophysiologic mechanisms and increased clinical experience. New insights in the relevance of detection of autoantibodies and development of autoimmunity have influenced the clinical pathway substantially. This review covers the pathomechanisms, incidence and optimized therapy of IFN-alpha-associated side effects.Keywords
This publication has 57 references indexed in Scilit:
- The course of melanoma-associated vitiligo: report of a caseMelanoma Research, 2006
- Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant MelanomaJournal of Clinical Oncology, 2006
- Effect of ondansetron, a 5-HT 3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled studyGut, 2005
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CJournal of Hepatology, 2005
- Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?Journal of Endocrinology, 2005
- Prophylactic SSRI during interferon alpha re‐therapy in patients with chronic hepatitis C and a history of interferon‐induced depressionJournal of Viral Hepatitis, 2005
- Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant MelanomaJournal of Clinical Oncology, 2004
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Clinical Toxicity of the InterferonsDrug Safety, 1994
- Suicide associated with alfa-interferon therapy for chronic viral hepatitisJournal of Hepatology, 1994